Classification
Compound class	Synthetic organic

IUPAC Name

N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide

International Nonproprietary Names
INN number	INN
10119	amcasertib

Synonyms

BBI-503 | BBI503

Comments

Amcasertib (BBI503) is a first-in-class, orally active, cancer stemness kinase inhibitor has been developed by Boston Biomedical for potential anticancer activity [1]. by targeting certain kinase enzymes it is reported to inhibit Nanog (NANOG; Q9H9S0) and other signalling pathways that control stem-cell replication, survival and differentiation. To date (April 2018) the only reports of BBI503 mechanism of action and clinical efficacy are in the form of meeting abstracts, and not in peer reviewed articles. Amcasertib is one of the chemical structures claimed in patent US8299106B2 [2], which were discussed as potential PDGFRα inhibitors therein.

Database Links
CAS Registry No.	1129403-56-0 (source: WHO INN record)
GtoPdb PubChem SID	363894218
PubChem CID	74403975
Search Google for chemical match using the InChIKey	QDWKGEFGLQMDAM-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	QDWKGEFGLQMDAM
Search PubMed clinical trials	amcasertib
Search PubMed titles	amcasertib
Search PubMed titles/abstracts	amcasertib
Search UniChem for chemical match using the InChIKey	QDWKGEFGLQMDAM-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	QDWKGEFGLQMDAM